Molecular staging by RT-PCR analysis for PSA and PSMA in peripheral blood and bone marrow samples is an independent predictor of time to biochemical failure following radical prostatectomy for clinically localized prostate cancer

Clinical and Experimental Metastasis

Volumn 21, Issue 6, 2004, Pages 495-505

  Mitsiades, Constantine S ^a,b   Lembessis, Peter ^a   Sourla, Antigone ^c   Milathianakis, Constantine ^d   Tsintavis, Athanassios ^d   Koutsilieris, Michael ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Endo/OncoResearch Laboratories   (Greece)

^d METAXA CANCER HOSPITAL   (Greece)

Author keywords

Pre operative risk stratification; Prostate cancer; PSA; PSMA; RT PCR

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RNA;

ARTICLE; BLOOD SAMPLING; BONE MARROW BIOPSY; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NUCLEOTIDE SEQUENCE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSRECTAL ULTRASONOGRAPHY; TRANSRECTAL ULTRASOUND GUIDED BIOPSY; TUMOR BIOPSY;

ANTIGENS, SURFACE; BONE MARROW; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT FAILURE;

EID: 12544260255     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10585-004-3217-0     Document Type: Article

References (55)

1. Labrie F, Dupont A, Cusan L et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 1993; 16(6): 499-509.
2. Brawer MK, Chetner MP, Beatie J et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol 1992; 147(3 Pt 2): 841-5.
3. Han M, Partin AW, Pound CR et al. Long-term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy. The 15-year Johns Hopkins experience. Urol Clin North Am 2001; 28(3): 555-65.
4. Rees MA, Resnick MI, Oesterling JE. Use of prostate-specific antigen, Gleason score, and digital rectal examination in staging patients with newly diagnosed prostate cancer. Urol Clin North Am 1997; 24(2): 379-88.
5. Olsson CA, de Vries GM, Buttyan R, Katz AE. Reverse transcriptase- polymerase chain reaction assays for prostate cancer. Urol Clin North Am 1997; 24(2): 367-78.
6. Moul JW, Kane CJ, Malkowicz SB. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy. Urol Clin North Am 2001; 28(3): 459-72.
7. Koutsilieris M, Lembessis P, Luu-The V, Sourla A. Repetitive and site-specific molecular staging of prostate cancer using nested reverse transcriptase polymerase chain reaction for prostate specific antigen and prostate specific membrane antigen. Clin Exp Metast 1999; 17(10): 823-30.
8. Sourla A, Lembessis P, Mitsiades C, Dimopoulos T, Skouteris M, Metsinis M et al. Conversion of nested reverse-transcriptase polymerase chain reaction from positive to negative status at peripheral blood during androgen ablation therapy is associated with long progression-free survival in stage D2 prostate cancer patients. Anticancer Res 2001; 21(5): 3565-70.
9. Kantoff PW, Halabi S, Farmer DA et al. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in men with hormone-refractory prostate cancer. J Clin Oncol 2001; 19(12): 3025-8.
10. Halabi S, Small EJ, Hayes DF, Vogelzang NJ, Kantoff PW. Prognostic significance of reverse transcriptase polymerase chain reaction for prostate-specific antigen in metastatic prostate cancer: A nested study within CALGB 9583. J Clin Oncol 2003; 21(3): 490-5.
11. Koutsilieris M, Dimopoulos MA, Doillon C, Sourla A, Reyes-Moreno C, Choki I. The molecular concept of prostate cancer. Cancer J 1996; 9: 89-94.
12. Gomella LG, Raj GV, Moreno JG. Reverse transcriptase polymerase chain reaction for prostate specific antigen in the management of prostate cancer. J Urol 1997; 158(2): 326-37.
13. Lerner SE, Blute ML, Zincke H. Risk factors for progression in patients with prostate cancer treated with radical prostatectomy. Semin Urol Oncol 1996; 14(2 Suppl 2): 12-20; discussion 21.
14. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol 2000; 164(1): 101-5.
15. D'Amico AV, Whittington R, Malkowicz SB et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 2000; 55(4): 572-7.
16. Rolfs A, Schuller I, Finckh U, Weber R. Biological material amenable to PCR. In Rolfs A (ed): PCR clinical diagnostics and research. Berlin: Springer-Verlag. p. 68-70.
17. Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 1982; 38(1): 163-70.
18. Partin AW, Piantadosi S, Sanda MG et al. Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 1995; 45(5): 831-8.
19. Debruyne FM, Witjes WP. Neoadjuvant hormonal therapy prior to radical prostatectomy: The European experience. Mol Urol 2000; 4(3): 251-6; discussion 257.
20. Partin AW, Yoo J, Carter HB et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993; 150(1): 110-4.
21. Ornstein DK, Smith DS, Rao GS et al. Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol 1997; 157(6): 2179-82.
22. Curran MJ, Bihrle W, 3rd. Dramatic rise in prostate-specific antigen after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999; 53(2): 423-4.
23. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N Engl J Med 2001; 344(18): 1373-7.
24. Luboldt HJ, Bex A, Swoboda A et al. Early detection of prostate cancer in Germany: A study using digital rectal examination and 4.0 ng/ml prostate-specific antigen as cutoff. Eur Urol 2001; 39(2): 131-7.
25. Wood DP, Jr., Banerjee M. Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival. J Clin Oncol 1997; 15(12): 3451-7.
26. Katz AE, de Vries GM, Benson MC et al. The role of the reverse-transcriptase polymerase chain reaction assay for prostate-specific antigen in the selection of patients for radical prostatectomy. Urol Clin North Am 1996; 23(4): 541-9.
27. Mejean A, Vona G, Nalpas B et al. Detection of circulating prostate derived cells in patients with prostate adenocarcinoma is an independent risk factor for tumor recurrence. J Urol 2000; 163(6): 2022-9.
28. de Cremoux P, Ravery V, Podgorniak MP et al. Value of the preoperative detection of prostate-specific-antigen-positive circulating cells by nested RT-PCR in patients submitted to radical prostatectomy. Eur Urol 1997; 32(1): 69-74.
29. Loric S, Dumas F, Eschwege P et al. Enhanced detection of hematogenous circulating prostatic cells in patients with prostate adenocarcinoma by using nested reverse transcription polymerase chain reaction assay based on prostate-specific membrane antigen. Clin Chem 1995; 41(12 Pt 1): 1698-704.
30. Ellis WJ, Vessella RL, Corey E et al. The value of a reverse transcriptase polymerase chain reaction assay in preoperative staging and followup of patients with prostate cancer. J Urol 1998; 159(4): 1134-8.
31. Lintula S, Stenman UH. The expression of prostate-specific membrane antigen in peripheral blood leukocytes. J Urol 1997; 157(5): 1969-72.
32. Zippelius A, Kufer P, Honold G et al. Limitations of reverse- transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol 1997; 15(7): 2701-8.
33. Gala JL, Loric S. Sensitivity or specificity of reverse transcriptase-polymerase chain reaction assays: the real challenge for molecular staging of prostatic carcinomas. Int J Cancer 1998; 77(1): 161-3.
34. Henke W, Loening SA. Detection of illegitimate transcripts of prostate-specific antigen mRNA in blood by reverse transcription-polymerase chain reaction. Int J Cancer 1998; 77(1): 164-5.
35. de la Taille A, Olsson CA, Katz AE. Molecular staging of prostate cancer: dream or reality? Oncology (Huntingt) 1999; 13(2): 187-94; discussion 194-8, 204-5 pas.
36. Fidler IJ. Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res 1990; 50(19): 6130-8.
37. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974; 34(5): 997-1004.
38. Koutsilieris M, Mitsiades C, Dimopoulos T et al. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. J Clin Endocrol Metab 2001; 86(12): 5729-36.
39. Koutsilieris M, Mitsiades CS. The concept of anti-survival factor therapy in advanced prostate cancer. Exp Opin Invest Drugs 2001.
40. Bauer JJ, Connelly RR, Sesterhenn IA et al. Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy. Cancer 1997; 79(5): 952-62.
41. Bauer JJ, Connelly RR, Seterhenn IA et al. Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 1998; 159(3): 929-33.
42. Graefen M, Karakiewicz PI, Cagiannos I et al. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2002; 20(15): 3206-12.
43. Katz AE, Olsson CA, Raffo AJ et al. Molecular staging of prostate cancer with the use of an enhanced reverse transcriptase-PCR assay. Urology 1994; 43(6): 765-75.
44. Wood DP, Jr., Banks ER, Humphreys S et al. Identification of bone marrow micrometastases in patients with prostate cancer. Cancer 1994; 74(9): 2533-40.
45. Eschwege P, Dumas F, Blanchet P et al. Haematogenous dissemination of prostatic epithelial cells during radical prostatectomy. Lancet 1995; 346(8989): 1528-30.
46. Katz AE, de Vries GM, Begg MD et al. Enhanced reverse transcriptase-polymerase chain reaction for prostate specific antigen as an indicator of true pathologic stage in patients with prostate cancer. Cancer 1995; 75(7): 1642-8.
47. Olsson CA, De Vries GM, Benson MC et al. The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol 1996; 77(3): 411-7.
48. Corey E, Arfman EW, Oswin MM et al. Detection of circulating prostate cells by reverse transcriptase-polymerase chain reaction of human glandular kallikrein (hK2) and prostate-specific antigen (PSA) messages. Urology 1997; 50(2): 184-8.
49. Deguchi T, Yang M, Ehara H et al. Detection of micrometastatic prostate cancer cells in the bone marrow of patients with prostate cancer. Br J Cancer 1997; 75(5): 634-8.
50. Melchior SW, Corey E, Ellis WJ et al. Early tumor cell dissemination in patients with clinically localized carcinoma of the prostate. Clin Cancer Res 1997; 3(2): 249-56.
51. Su SL, Heston WD, Perrotti M et al. Evaluating neoadjuvant therapy effectiveness on systemic disease: use of a prostatic-specific membrane reverse transcription polymerase chain reaction. Urology 1997; 49(3A Suppl): 95-101.
52. Gala JL, Heusterspreute M, Loric S et al. Expression of prostate-specific antigen and prostate-specific membrane antigen transcripts in blood cells: implications for the detection of hematogenous prostate cells and standardization. Clin Chem 1998; 44(3): 472-81.
53. Grasso YZ, Gupta MK, Levin HS et al. Combined nested RT-PCR assay for prostate-specific antigen and prostate-specific membrane antigen in prostate cancer patients: correlation with pathological stage. Cancer Res 1998; 58(7): 1456-9.
54. Bianco FJ, Jr., Wood DP, Jr., Gomes de Oliveira J et al. Proliferation of prostate cancer cells in the bone marrow predicts recurrence in patients with localized prostate cancer. Prostate 2001; 49(4): 235-42.
55. Thomas J, Gupta M, Grasso Y et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol 2002; 20(15): 3213-8.